Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs Bevacizumab in Diabetic Maculopathy
NCT06850571Phase 4Recruiting
- Sponsor
- Al-Mustansiriyah University
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in diabetic macular edema (DME), sponsored by Al-Mustansiriyah University. Started Feb 2025; status: recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06850571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850571.